Healthcare
Live Price
Offline$49.74
-2.59% today
1Y Change
+30.43%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Roche Holding AG (RHHBY) is a Healthcare stock with a market cap of $253.45B and listed on OTC. The stock last traded around $49.74 and up 30.4% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +1.5%, EPS growth of +55.5%, a dividend yield of 3.1%. What stands out right now is revenue +1.5%, EPS +55.5%, free cash flow -10.8% with operating margin 28.9% and ROIC 18.8%. The dividend matters to the case here, with a current yield around 3.1%. Valuation sits in the middle of the pack at P/E 19.7 and price/sales 4.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines RHHBY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RHHBY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RHHBY Max Drawdown
-21.77%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RHHBY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$62.8B
-4.6% YoY
FY Net Income
$13.9B
+12.1% YoY
Free Cash Flow
$16.0B
+20.1% YoY
Revenue Growth
+1.5%
EPS Growth
+55.5%
Gross Margin
73.5%
Net Margin
20.9%
Income statement
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 63.4B | 62.4B | 60.4B | 65.8B | 62.8B |
| Gross Profit | 46.7B | 46.1B | 44.8B | 47.9B | 43.1B |
| Operating Income | 18.5B | 13.4B | 15.4B | 17.5B | 17.3B |
| EBITDA | 21.7B | 16.6B | 18.4B | 24.1B | 22.2B |
| Net Income | 12.9B | 8.3B | 11.5B | 12.4B | 13.9B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.6B | 7.0B | 5.4B | 5.0B | 6.8B |
| Total Assets | 100.8B | 101.8B | 90.5B | 88.2B | 92.3B |
| Total Liabilities | 62.9B | 65.6B | 57.2B | 56.1B | 64.0B |
| Shareholder Equity | 33.8B | 31.8B | 29.3B | 28.0B | 24.5B |
| Total Debt | 31.7B | 36.4B | 30.8B | 26.5B | 32.6B |
| Net Debt | 26.1B | 29.4B | 25.4B | 21.6B | 25.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
20.6B
+15.0% YoY
Capital Expenditures
4.5B
+0.1% YoY
Free Cash Flow
16.0B
+20.1% YoY
Key ratios
Gross Margin
73.5%
Operating Margin
28.9%
Net Margin
20.9%
ROE
41.2%
Debt / Equity
0.94x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.